Giiant Pharma - About the company
Giiant Pharma is a seed company based in Quebec City (Canada), founded in 2014 by Elizabeth Kwong. It operates as a Developer of colon-specific anti-inflammatory therapy for ulcerative colitis. Giiant Pharma has raised $12.3M in funding from investors like CQDM, Genesys Capital and Amplitude. The company has 314 active competitors, including 118 funded and 64 that have exited. Its top competitors include companies like Denali Therapeutics, Septerna and Evommune.
Company Details
Developer of colon-specific anti-inflammatory therapy for ulcerative colitis. The company has developed a proprietary Gastro-Intestinal-Induced Anti-inflammatory technology (GiiAnt), which develops potent anti-inflammatory agents with a colon-specific carrier covalently bound to the active moiety in a way that the carrier is cleaved off locally by the large intestine microbiota. The company's pipeline includes GT-2108 is a gut-restricted, colon-specific PDE4 prodrug inhibitor, and GT-1908 for Crohn’s Disease treatment.
- Website
- giiant.com
- Social
- Phone Number
- +1 **********
- Registered Address
- 500 boulevard Cartier O, Laval
Key Metrics
Founded Year
2014
Location
Quebec City, Canada
Stage
Seed
Total Funding
$12.3M in 2 rounds
Latest Funding Round
Ranked
107th among 314 active competitors
Employee Count
4 as on May 31, 2026
Similar Companies
Legal entities associated with Giiant Pharma
Giiant Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
GIIANT PHARMA INC. CIN: 901945-6 , Canada, Active | Sep 15, 2014 | - | - | - |
Sign up to download Giiant Pharma's company profile
Giiant Pharma's funding and investors
Giiant Pharma has raised a total funding of $12.3M over 2 rounds. Its first funding round was on May 21, 2021. Its latest funding round was a Seed round on Jun 30, 2021 for $*****. 2 investors participated in its latest round. Giiant Pharma has 8 institutional investors.
Here is the list of recent funding rounds of Giiant Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 30, 2021 | 8763796 | Seed | 6314762 | 2841340 | 1541642 | 7290414 |
May 21, 2021 | 5956775 | Seed | 8677187 | 2151994 |
Access funding benchmarks and valuations. Sign up today!View details of Giiant Pharma's funding rounds and investors
Giiant Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Giiant Pharma is Elizabeth Kwong.
Here are the details of Giiant Pharma's key team members:
- Elizabeth Kwong: Co-Founder of Giiant Pharma. Contact Info: 1 phone number
Giiant Pharma's Board of Directors
Giiant Pharma's board has 3 active members. Jesse Paterson, Jamie Stiff and Patricia Escoffier are independent board members.Here is the list of Giiant Pharma's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Independent board member | - | Current | 4y 5m | |
esxyqkt | Independent board member | - | Current | 2y 8m |
jkprhbb | Independent board member | - | Current | 9y 7m |
View details of Giiant Pharma's Founder profiles and Board Members
Giiant Pharma's employee count trend
Giiant Pharma has 4 employees as of May 26. Here is Giiant Pharma's employee count trend over the years:
Uncover Giiant Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Giiant Pharma's Competitors and alternates
Top competitors of Giiant Pharma include Denali Therapeutics, Septerna and Evommune. Here is the list of Top 10 competitors of Giiant Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 72/100 | |
2nd | Septerna 2020, San Bruno (United States), Public | Developer of GPCR drug discovery platform for multiple diseases | $250M | 71/100 | |
3rd |  Evommune 2020, Sacramento (United States), Public | Developer of therapeutic options for chronic inflammatory disorders | $276M | 69/100 | |
4th |  Upstream Bio 2021, Waltham (United States), Public | Developer of therapeutics for allergic and inflammatory diseases | $400M | 67/100 | |
5th |  Odyssey 2018, Cambridge (United States), Public | Developer of immunotherapeutics for immunological and cancer diseases | $717M | 66/100 | |
6th |  Ventyx Biosciences 2018, Encinitas (United States), Acquired | Developer of therapeutics to treat autoimmune diseases | $165M | 66/100 | |
7th | CalciMedica 2006, San Diego (United States), Public | Developer of CRAC channel inhibitor drugs for inflammatory diseases | $76.7M | 64/100 | |
8th |  Sonoma Biotherapeutics 2012, San Francisco (United States), Series B | Developer of T-cell-based therapies for autoimmune and degenerative diseases | $335M | 64/100 | |
9th | Gesynta Pharma 2017, Solna (Sweden), Series B | Developer of oral therapies for treating chronic inflammatory conditions | $31.1M | 63/100 | |
10th | Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction | $122M | 62/100 | ||
107th | Giiant Pharma 2014, Quebec City (Canada), Seed | Developer of colon-specific anti-inflammatory therapy for ulcerative colitis | $12.3M | 38/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Giiant Pharma's competitors? Click here to see the top ones
Giiant Pharma's Investments and acquisitions
Giiant Pharma has made no investments or acquisitions yet.
News related to Giiant Pharma
•
•
Palisade stock rallies as high as 180% on IBD drug licensing dealSeeking Alpha•Sep 07, 2023•Palisade Bio, Giiant Pharma
•
•
Genesys Capital appoints Dr. Maxime Ranger as Venture PartnerBusiness Wire•Jan 13, 2022•Genesys Capital, Giiant Pharma
•
•
•
Giiant Pharma extends seed round with $1.25MDrug Delivery Business•Jun 30, 2021•Giiant Pharma, AQC Capital, CQDM
•
Giiant Pharma Inc Strengthens its Board of Directors with the Appointment of Dr. Marie LindnerBusiness Wire•Jun 17, 2021•Giiant Pharma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Giiant Pharma
Explore our recently published companies
- Danieli Corus - India based, 2001 founded, Unfunded company
- Satyesh Brinechem - Kutch based, 1923 founded, Unfunded company
- Solaris ChemTech - Gurugram based, 2000 founded, Acquired company
- Pinus-Buchhaltungssoftware - Switzerland based, Unfunded company
- Unilever Professional - Mumbai based, 2021 founded, Unfunded company
- Cresus - Switzerland based, Unfunded company
